News und Analysen
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be presenting eight posters
Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease
Regulatory News:
Sensorion, (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the
Valbiotis gibt den letzten Besuch des letzten Patienten in der Phase II/III REVERSE-IT Studie zu TOTUM•63 in Partnerschaft mit Nestlé Health Science bekannt
Valbiotis (FR0013254851 - ALVAL, PEA / SME förderungswürdig (Paris:ALVAL), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Sensorion Discloses No Exposure To Silicon Valley Bank Closure
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has
Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing
EQS-News: Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr.
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology
Regulatory News:
POXEL SA (Euronext : POXEL – FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its
Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulatory News:
POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Valbiotis veröffentlicht Brief an die Aktionäre und Finanzkommunikationskalender für 2023
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA / KMU-qualifiziert), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich auf wissenschaftliche Innovationen
EQS-News: Abivax publishes a prospectus in the context of its capital increase
Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating
Sensorion announces R&D Day focusing on its Gene Therapy programs
Regulatory News:
Sensorion, (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and
Sartorius Stedim Biotech SA: Information on Document Availability
EQS-News: Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO
GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 1.44 euros per share to the Annual Shareholders’ Meeting
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within